The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
B A OppenheimS Kusne

Abstract

Amphotericin B colloidal dispersion (ABCD), a novel formulation of amphotericin B and cholesteryl sulfate in a 1:1 ratio, was developed to reduce the toxicity of amphotericin B yet retain its antifungal efficacy. In an open-label trial, ABCD at dosages as high as 6 mg/(kg.d) was administered to 168 patients with documented or presumed systemic mycoses. All patients had responded incompletely to at least 7 days' treatment with conventional amphotericin B (CAB), had experienced CAB-induced nephrotoxic effects, had preexisting renal impairment, or had experienced other CAB-related, treatment-limiting toxic effects. The clinical response to ABCD could be evaluated in 97 patients. Complete clinical response or improvement was noted in 48 (49%) of them after a mean treatment duration of 18.5 days. All 168 enrolled patients were evaluated with regard to safety of the treatment. Even at daily doses as high as 6 mg/kg, and mean and median cumulative doses of 4.0 g and 2.4 g, respectively, ABCD had little renal toxicity: the mean change in serum level of creatinine from baseline to final value was -0.02 mg/dL. Hypokalemia developed in eight patients (5%). This study provides preliminary evidence that ABCD is effective in treating invasiv...Continue Reading

Citations

Jan 1, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R Herbrecht
Jul 1, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B BeovićJ Pretnar
Nov 14, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·V J AnttilaP Ruutu
Apr 20, 2006·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S B GiroisB G P Revol
Feb 16, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S B GiroisB G P Revol
Aug 13, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J W HiemenzT J Walsh
Sep 1, 1999·The Journal of Infection·R J Hay
Jul 14, 1999·Diagnostic Microbiology and Infectious Disease·M F VandenBerghA Voss
Jun 15, 1999·Pharmaceutical Science & Technology Today·I BekerskyI Lawrence
Apr 8, 2003·The Lancet Infectious Diseases·David W DenningUNKNOWN British Society for Medical Mycology
Dec 4, 2003·The Lancet Infectious Diseases·Philippe EggimannDidier Pittet
Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·M Ellis
Apr 8, 1998·British Journal of Haematology·M D Richardson, M H Kokki
Oct 9, 1999·International Journal of Dermatology·R J Hay
Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D A StevensG A Pankey
Aug 31, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J CollazosS Ibarra
Jul 30, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Raleigh BowdenJohn R Wingard
Jul 29, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luis Ostrosky-ZeichnerStuart H Cohen
Sep 3, 1999·The Journal of Antimicrobial Chemotherapy·V T Andriole
Apr 9, 1999·Medicine·D L Paterson, N Singh
Mar 20, 1999·Current Opinion in Pediatrics·T LehrnbecherS J Chanock
Jun 23, 2000·Journal of Pediatric Hematology/oncology·E S SandlerL Pietrelli
Oct 16, 2008·Clinical Microbiology Reviews·David TrofaJoshua D Nosanchuk
May 27, 2008·Cost Effectiveness and Resource Allocation : C/E·Harrell W ChessonKathryn Koski
Mar 7, 2014·Clinical Pharmacokinetics·Chris StockmannCatherine M T Sherwin
Jul 2, 2005·Expert Opinion on Emerging Drugs·Sevtap Arikan, John H Rex
Mar 4, 2008·Expert Opinion on Pharmacotherapy·Read Pukkila-Worley, Eleftherios Mylonakis
May 4, 1999·Cancer Investigation·B S Zingman
Jan 8, 2016·Infectious Disease Clinics of North America·Jeniel E Nett, David R Andes
Jan 30, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J P Donnelly, B E De Pauw
May 27, 2009·British Journal of Haematology·Livio PaganoLuana Fianchi
Oct 10, 2006·Journal of Chemotherapy·L PaganoG Leone
Aug 13, 2003·The Veterinary Clinics of North America. Small Animal Practice·Amy M Grooters, Joseph Taboada
May 4, 1999·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·C Viscoli, E Castagnola
Mar 28, 2003·The Journal of Hospital Infection·D P KontoyiannisG Samonis
Feb 28, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Christoph M. Tang, Ian C. J. W. Bowler
Apr 2, 2011·The Lancet Infectious Diseases·Hsin-Yun Sun, Nina Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.